ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

American College of Cardiology
  • 3.7 (53)
  • 医学
  • 一日一更

The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.

  1. 2天前

    Behind the 2025 ACC/AHA Acute Coronary Syndrome Guideline

    The 2025 ACC/AHA Acute Coronary Syndrome guideline is the first major update since 2013, incorporating a decade of new evidence and clinical insights. The writing committee stayed on track and on time, reaching consensus on key recommendations, including checklist-based Class I and II interventions before discharge. They thoughtfully addressed legacy practices and controversial studies to ensure clarity and relevance. While some emerging data didn’t meet the threshold for formal inclusion, areas like discharge antiplatelet therapy, coronary imaging, and mechanical support devices were flagged as important for clinicians to monitor. The result is a practical, evidence-based tool to guide bedside decision-making.    In this interview, Drs. Roxana Mehran and Sunil V. Rao take listeners “Behind the 2025 Acute Coronary Syndrome Guidelines.”   Subscribe on Apple Podcasts | Subscribe to ACCEL

    11 分钟

  2. 8月26日

    Top Takeaways From the 2025 ACC/AHA Acute Coronary Syndrome Guideline

    The 2025 ACC/AHA Acute Coronary Syndrome (ACS) Guideline clarifies diagnostic distinctions using electrocardiogram changes, troponin levels, and imaging tools such as coronary CT angiography and echocardiography in the emergency setting. Updates in lipid-lowering strategies and antiplatelet therapy reflect a more personalized approach to risk reduction and long-term care. These recommendations aim to streamline acute decision-making and improve outcomes across the ACS spectrum.    In this interview, Drs. Sidney C. Smith Jr. and Michelle L. O'Donoghue discuss “Top Takeaways From the 2025 ACC/AHA Acute Coronary Syndrome Guideline.”    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    18 分钟

  3. 8月19日

    Risk vs. Benefit in Chronic Total Occlusion Revascularization

    Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) is a procedure used to open coronary arteries that have been completely blocked for an extended period. It offers benefits like reduced angina and improved quality of life but carries risks such as vessel injury, heart attack, and procedural failure. Before considering CTO PCI, physicians typically optimize patients on anti-anginal medications—such as beta-blockers, nitrates, and calcium channel blockers—to manage symptoms and evaluate the need for intervention.  In this interview, Drs. Anthony N. DeMaria and Lindsey Cilia examine “Risk versus Benefit in Chronic Total Occlusion Revascularization.”  Subscribe on Apple Podcasts | Subscribe to ACCEL

    12 分钟

  4. 8月12日

    LAAO vs. DOAC for Stroke Prevention in AFib

    While blood thinners like warfarin and direct oral anticoagulants (DOACs) remain the standard for stroke prophylaxis, left atrial appendage occlusion (LAAO) devices offer a non-pharmacologic alternative for patients at high bleeding risk. Recent trials have shown that LAAO can be as effective as anticoagulants in preventing stroke and may be a viable option, especially for patients who cannot tolerate long-term anticoagulation.    In this interview, Drs. Anthony N. DeMaria and Dhanunjaya Lakkireddy explore the evolving landscape of stroke prevention in patients with atrial fibrillation, focusing on the comparison between traditional blood thinners and LAAO.    Subscribe on Apple Podcasts | Subscribe to ACCEL

    15 分钟

  5. 8月5日

    Why Are They Still Dyspneic? Post PE Syndrome Workup and Management

    Persistent symptoms after an acute pulmonary embolism (PE) may indicate post-pulmonary embolism syndrome (PPES), a condition affecting up to 50% of patients. The most important consideration in managing PPES is to carefully evaluate and differentiate it from other potential causes of ongoing shortness of breath, particularly chronic thromboembolic pulmonary hypertension (CTEPH), which requires targeted treatment. How can clinicians best differentiate between PPES and other causes of persistent symptoms following an acute PE?    In this interview, Drs. Dipti Itchhaporia and Paul R. Forfia discuss “Why Are They Still Dyspneic? Post PE Syndrome Workup and Management.”    Subscribe on Apple Podcasts| Subscribe to ACCEL

    12 分钟

  6. 7月29日

    Palliative Care Across the Spectrum of Biological Age in Heart Failure

    Palliative care supports heart failure patients by guiding complex medical decisions, managing symptoms, and enhancing quality of life. Despite being a guideline-recommended therapy, it remains underused—referrals are 45% lower for heart failure patients than for cancer patients with similar prognoses. Collaboration between cardiology and palliative care teams ensures that patients and caregivers receive goal-aligned care and the best possible quality of life.   In this interview, Dr. Mary Norine Walsh and Ms. Jill A. Patton explore how palliative care can help patients across the span of their illness.   Related References:   1.  Chuzi S, Saylor MA, Allen LA, et al. Integration of Palliative Care into Heart Failure Care: Consensus-Based Recommendations from the Heart Failure Society of America. J Card Fail. 2025;31(3):559-573. doi:10.1016/j.cardfail.2024.10.435  2. Gelfman LP, Blum M, Ogunniyi MO, McIlvennan CK, Kavalieratos D, Allen LA. Palliative Care Across the Spectrum of Heart Failure. JACC Heart Fail. 2024;12(6):973-989. doi:10.1016/j.jchf.2024.01.010   Subscribe on Apple Podcasts | Subscribe to ACCEL

    12 分钟

  7. 7月22日

    ACCEL Lite: Hypertension Diagnosis and Management: Renal Denervation and Newer Agents on the Horizon

    Recent clinical trials demonstrate that intensive blood pressure lowering—targeting systolic levels below 120 mm Hg—can significantly reduce cardiovascular events and mortality, even among older adults, individuals with diabetes, and those with chronic kidney disease. This challenges the long-standing belief that looser blood pressure targets are safer for older patients, showing instead that with proper monitoring, tighter control offers substantial net benefits for most high-risk groups.   In this interview, Dr. Alison L. Bailey and Dr. Keith C. Ferdinand explore the evolving landscape of hypertension management, highlighting new evidence supporting the benefits of tight blood pressure control across diverse populations.    Suggested Materials:   1. Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245-255. doi:10.1016/S0140-6736(24)01028-6  2. Bi Y, Li M, Liu Y, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. 2025;392(12):1155-1167. doi:10.1056/NEJMoa2412006  3. Reddy TK, Nasser SA, Pulapaka AV, Gistand CM, Ferdinand KC. Tackling the Disproportionate Burden of Resistant Hypertension in US Black Adults. Curr Cardiol Rep. 2024;26(11):1163-1171. doi:10.1007/s11886-024-02115-5   Subscribe on Apple Podcasts | Subscribe to ACCEL

    15 分钟

  8. 7月15日

    What's the Best Time to Revascularize the Non-culprit Lesions in MVD

    Rapid emergency medical services transport to a percutaneous coronary intervention (PCI)-capable hospital is critical for timely intervention and management of life-threatening arrhythmias in ST-elevation myocardial infarction patients. Upon emergency room arrival, immediate transfer to the cath lab is essential to restore perfusion and improve both short- and long-term cardiovascular outcomes, as recommended by clinical guidelines. Interventional cardiologists must also be adept at managing culprit lesions in multivessel disease (MVD) and addressing complications like the no-reflow phenomenon during PCI.   In this interview, Drs. Dipti Itchhaporia and Nabil Farag discuss “What's the Best Time to Revascularize the Non-culprit Lesions in MVD.”   Suggested Materials:  Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes [published correction appears in Eur Heart J. 2024 Apr 1;45(13):1145. doi: 10.1093/eurheartj/ehad870.]. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191  Mehta SR, Wood DA, Meeks B, et al. Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. Am Heart J. 2019;215:157-166. doi:10.1016/j.ahj.2019.06.006   Subscribe on Apple Podcasts | Subscribe to ACCEL

    9 分钟
查看全部 98 集

3.7
共 5 分
53 个评分

关于

The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.

信息

你可能还喜欢